174 related articles for article (PubMed ID: 37921538)
1. Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study.
Tsang RS; Agrawal U; Joy M; Byford R; Robertson C; Anand SN; Hinton W; Mayor N; Kar D; Williams J; Victor W; Akbari A; Bradley DT; Murphy S; O'Reilly D; Owen RK; Chuter A; Beggs J; Howsam G; Sheikh A; Richard Hobbs FD; Lusignan S
J R Soc Med; 2024 Apr; 117(4):134-148. PubMed ID: 37921538
[TBL] [Abstract][Full Text] [Related]
2. Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study.
Tsang RS; Joy M; Byford R; Robertson C; Anand SN; Hinton W; Mayor N; Kar D; Williams J; Victor W; Akbari A; Bradley DT; Murphy S; O'Reilly D; Owen RK; Chuter A; Beggs J; Howsam G; Sheikh A; Hobbs FR; de Lusignan S
Euro Surveill; 2023 Jan; 28(3):. PubMed ID: 36695484
[TBL] [Abstract][Full Text] [Related]
3. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
[TBL] [Abstract][Full Text] [Related]
4. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
5. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
7. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
9. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.
Kim J; Kwon HY; Ahn SJ
JAMA Ophthalmol; 2024 Jun; 142(6):522-528. PubMed ID: 38662361
[TBL] [Abstract][Full Text] [Related]
11. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
[TBL] [Abstract][Full Text] [Related]
13. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study.
de Lusignan S; Tsang RSM; Akinyemi O; Lopez Bernal J; Amirthalingam G; Sherlock J; Smith G; Zambon M; Howsam G; Joy M
JMIR Public Health Surveill; 2022 Mar; 8(3):e25803. PubMed ID: 35343907
[TBL] [Abstract][Full Text] [Related]
17. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
18. Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018).
Cross JW; Joy M; McGee C; Akinyemi O; Gatenby P; de Lusignan S
Vaccine; 2020 May; 38(22):3869-3880. PubMed ID: 32299719
[TBL] [Abstract][Full Text] [Related]
19. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
[TBL] [Abstract][Full Text] [Related]
20. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
